Association between blood nicotinamide adenine dinucleotide levels and blood laboratory parameters at baseline and after nicotinamide mononucleotide supplementation in middle-aged healthy individuals: post hoc analysis of a randomized, double-blinded, placebokontrollerad clinical trial.

Detta var en post hoc-analys av en randomiserad, dubbelblind klinisk studie med friska deltagare i medelåldern. Huvudstudien jämförde dagligt nikotinamidmononukleotid i doserna 300, 600 eller 900 mg med placebo under 60 dagar. Analysen omfattade 80 personer med en medelålder på 49,4 år. Baseline blood NAD was 7.21 nM, with an interquartile range of 5.5 to 10.6 nM.

The analysis related NAD concentrations and NAD changes to routine laboratory parameters. Each 1 nM higher baseline NAD was associated with higher lymphocytes, triglycerides and liver enzymes, alongside lower neutrophils and high-density lipoprotein. Increases in NAD were associated with small increases in haemoglobin, red blood cells, mean corpuscular haemoglobin concentration and uric acid. For example, each 1 nM NAD increase was associated with a 0.027% increase in haemoglobin and a 0.025% increase in red blood cells.

These are associations from a secondary analysis, not proof that NMN improves oxygen delivery, health or longevity. No functional, disease or survival endpoint is reported. The mixed laboratory associations also do not support a simple claim that higher NAD produces uniformly favourable blood markers.

NMN-induced increases in blood NAD were associated with higher red-cell parameters, potentially indicating enhanced oxygen-carrying capacity.